Patent · US Active

Salts of dasatinib in amorphous form

US9884857B2 · kind B2 · utility

13Cited by

8References

18Claims

0Family size

Assignee

BASF SE

Inventors

Andreas Hafner · Gelterkinden, CH
Fritz Blatter · Reinach, CH
Martin Szelagiewicz · Münchenstein, CH
Bernd Siebenhaar · Kandern, DE
Tiziana Chiodo · Mannheim, DE
Tobias Hintermann · Therwil, CH
Beate Salvador · Ellerstadt, DE
Marcus Vossen · Schifferstadt, DE

Key dates

Filing date	Jul 22, 2014
Grant date	Feb 6, 2018
Priority date	—
Expiry date	Jul 22, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D275/06
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.